Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Surrozen, Inc. filings on SEC EDGAR ↗
Surrozen, Inc. reported a net loss of $207.1 million for the nine months ended September 30, 2026, significantly higher than the $58.9 million loss in the prior year period, primarily driven by a $111.5 million loss on the change in fair value of tranche liabilities. Total revenue for the nine-month period was $10.0 million, derived from collaboration and license revenue, while operating expenses increased to $48.5 million due to higher research and development costs.
Surrozen reported Q3 2026 financial results and announced the expansion of its Phase 2a DUET study for SZN-8141 from 60 to 150 patients. The company strengthened its balance sheet in October 2026 by closing a $95.1 million private placement tranche and raising $29.8 million via its ATM program, extending its cash runway into 2029.
Term
Q3 2026
“We have made important progress advancing Surrozen into its next stage of development, with the first patient dosed in the SZN-8141 DUET study and plans to significantly expand Phase 2a enrollment from approximately 60 to 150 patients. The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”
Craig Parker, President and Chief Executive Officer